Hematology/Oncology

Top Story

Imetelstat demonstrates clinical activity for myelofibrosis, but may cause myelosuppression

September 2, 2015

The telomerase inhibitor imetelstat demonstrates clinical activity in patients with myelofibrosis, according to the results of a pilot study.

However, imetelstat (Geron Corporation) may potentially cause clinically significant myelosuppression, the researchers reported.

Vitamin K antagonists do not affect bone mineral density, fracture risk In the Journals

Vitamin K antagonists do not affect bone mineral density, fracture risk

September 2, 2015
Vitamin K antagonists do not increase the risk for fracture or reduce bone mineral density, according to findings published in the Journal of Thrombosis and
Worth Building

Back-to-school reminder for parents and students: Check out college tax credits

September 2, 2015
With another school year here, the Internal Revenue Service reminds parents and students that now is a good time to see if they will qualify for either of two college…
FDA News

FDA approves Varubi for chemotherapy-induced nausea, vomiting

September 2, 2015
The FDA today approved rolapitant for the treatment of delayed-phase nausea and vomiting in patients with cancer who are undergoing chemotherapy.Rolapitant (Varubi…
In the Journals

Histologic regression may predict SLNB benefit in melanoma

September 2, 2015
Sentinel lymph node positivity occurred less frequently in patients with primary melanoma who had histologic regression, according to the results of a systemic review…
More News Headlines »
CME
Immunotherapy Updates 2015: FOCUS on NSCLC

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Updates in Immunotherapy – Philadelphia 2015

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »
morganatic-roan morganatic-roan